PT709097E - Anticorpo anti-fas para a doenca reumatica - Google Patents

Anticorpo anti-fas para a doenca reumatica

Info

Publication number
PT709097E
PT709097E PT95115210T PT95115210T PT709097E PT 709097 E PT709097 E PT 709097E PT 95115210 T PT95115210 T PT 95115210T PT 95115210 T PT95115210 T PT 95115210T PT 709097 E PT709097 E PT 709097E
Authority
PT
Portugal
Prior art keywords
fas
monoclonal antibody
rheumatic disease
fas antibody
synovial cells
Prior art date
Application number
PT95115210T
Other languages
English (en)
Inventor
Kusiki Nishioka
Shin Yoneyama
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of PT709097E publication Critical patent/PT709097E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT95115210T 1994-09-27 1995-09-27 Anticorpo anti-fas para a doenca reumatica PT709097E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP27013494 1994-09-27

Publications (1)

Publication Number Publication Date
PT709097E true PT709097E (pt) 2003-03-31

Family

ID=17482032

Family Applications (1)

Application Number Title Priority Date Filing Date
PT95115210T PT709097E (pt) 1994-09-27 1995-09-27 Anticorpo anti-fas para a doenca reumatica

Country Status (9)

Country Link
US (1) US6086877A (pt)
EP (1) EP0709097B1 (pt)
KR (1) KR100371000B1 (pt)
AT (1) ATE226447T1 (pt)
CA (1) CA2158822C (pt)
DE (1) DE69528624T2 (pt)
DK (1) DK0709097T3 (pt)
ES (1) ES2182860T3 (pt)
PT (1) PT709097E (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830469A (en) * 1993-10-14 1998-11-03 Immunex Corporation Fas antagonists and uses thereof
IL123756A0 (en) * 1997-03-21 1998-10-30 Sankyo Co Humanized anti-human FAS antibody
DE69938451T2 (de) 1998-06-18 2009-04-09 Imed Ab Fas peptide und antikörper zur modulierung von apoptosis
CZ20014181A3 (cs) * 1999-05-24 2002-03-13 Sankyo Company Limited Farmaceutický prostředek obsahující protilátku a pouľití protilátky
US6787136B1 (en) * 1999-09-03 2004-09-07 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of inflammatory disease using cadherin-11 modulating agents
AU2002210926B2 (en) 2000-10-24 2005-12-15 Shunichi Shiozawa Genomes participating in rheumatoid arthritis, method of the diagnosis thereof, method of evaluating the onset possibility thereof, diagnostic kit for detecting them and therapeutic method and remedies for rheumatoid arthritis
US20060104951A1 (en) * 2004-11-16 2006-05-18 Mountz John D Akt and regulation of RA synovial fibroblast apoptosis
US20070224184A1 (en) * 2006-02-22 2007-09-27 The Research Foundation Of The State University Of New York Method for treating cellulite
US10071143B1 (en) 2007-05-03 2018-09-11 The Research Foundation For The State University Of New York Methods for non-surgical treatment of carpal tunnel syndrome
EP2322220B1 (en) * 2008-08-01 2014-01-01 Axis, Inc. Therapeutic agent or preventive agent for osteoarthritis
EP2529751A4 (en) * 2010-01-29 2013-07-31 Axis Inc INJECTABLE SOLUTION WITH A MEANS FOR THE TREATMENT OF OSTEOARTHRITIS
KR20120115383A (ko) * 2010-01-29 2012-10-17 가부시키가이샤 아크시스 변형성 관절증 치료 또는 예방용 의약 조성물 및 이의 제조 방법
US8877188B2 (en) 2010-05-04 2014-11-04 The Brigham And Women's Hospital, Inc. Detection and treatment of non-dermal fibrosis
BR112014017229B1 (pt) 2012-01-12 2022-05-17 Auxilium International Holdings, Inc Ácido nucleico recombinante, cassette de expressão, vetor, célula hospedeira recombinante, método de produção da colagenase i ou ii, colagenase i ou ii, composição farmacêutica, e método de produção de um produto de droga
US9636385B2 (en) 2012-10-24 2017-05-02 The Research Foundation For The State University Of New York Use of collagenase to treat glaucoma
WO2016100301A1 (en) 2014-12-15 2016-06-23 The Brigham And Women's Hospital, Inc. Use of cadherin-11 antagonists to treat obesity-associated conditions and other metabolic disorders
US11123280B2 (en) 2017-03-01 2021-09-21 Endo Ventures Limited Method of assessing and treating cellulite
EP3601556A2 (en) 2017-03-28 2020-02-05 Endo Ventures Limited Improved method of producing collagenase

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58201712A (ja) * 1982-05-18 1983-11-24 Green Cross Corp:The 脂肪乳剤
JPS6051105A (ja) * 1983-08-30 1985-03-22 Green Cross Corp:The プロスタグランジン脂肪乳剤
JPH02237935A (ja) * 1989-03-10 1990-09-20 Bio Kagaku Kenkyusho:Kk エイズ処置剤
WO1991010448A1 (en) * 1990-01-19 1991-07-25 German Cancer Research Center A cell surface antigen associated with cellular apoptosis
DE69233441T2 (de) * 1991-04-26 2005-10-13 Osaka Bioscience Institute, Suita Menschliches Zelloberflächen-Antigen codierende DNA
EP0603194A4 (en) * 1991-07-05 1994-12-07 Seragen Inc TO THE RECEPTOR OF THE EPIDERMAL GROWTH FACTOR TARGETED MOLECULES FOR TREATING INFLAMMABLE ARTHRITIS.
EP0623598A4 (en) * 1992-08-19 1997-05-02 Otsuka Pharma Co Ltd APOPTOSIS REGULATOR.
US5830469A (en) * 1993-10-14 1998-11-03 Immunex Corporation Fas antagonists and uses thereof
KR960704938A (ko) * 1993-10-14 1996-10-09 그리스토퍼 엘. 와이트 Fas 길항제 및 그의 용도(Fas Antagonists and Uses Thereof)

Also Published As

Publication number Publication date
EP0709097A1 (en) 1996-05-01
KR960010024A (ko) 1996-04-20
US6086877A (en) 2000-07-11
ES2182860T3 (es) 2003-03-16
KR100371000B1 (ko) 2003-07-12
DE69528624T2 (de) 2003-06-26
CA2158822C (en) 2008-12-23
EP0709097B1 (en) 2002-10-23
CA2158822A1 (en) 1996-03-28
DE69528624D1 (de) 2002-11-28
DK0709097T3 (da) 2003-02-24
ATE226447T1 (de) 2002-11-15

Similar Documents

Publication Publication Date Title
PT709097E (pt) Anticorpo anti-fas para a doenca reumatica
Leung et al. Operative treatment of displaced intra-articular fractures of the calcaneum. Medium-term results
Verneuil et al. Interstitial granulomatous dermatitis with cutaneous cords and arthritis: a disorder associated with autoantibodies
BR0213846A (pt) métodos de induzir seletivamente a apoptose nas células alvo que expressam dr5, de inibir a proliferação de células alvo que expressam dr5 e de tratar um paciente tendo uma doença inflamatória ou doença autoimune, e, composição
BR0312947A (pt) terapias para insuficiência renal empregando-se interferon-beta
FI840219A (fi) Human-humanhybridom foer neoplasmer.
UY28170A1 (es) Preparacion y tratamiento para las enfermedades desmielinizantes y paralisis mediante la aplicacion de agentes remielinizantes.
TR199901417T2 (xx) Analjezik etkisi olan yeni bile�imler.
NO20001238D0 (no) Monoklonalt antistoff som induserer apoptose
IT8567350A1 (it) Dispositivo per la fabbricazione di corpi assorbenti, particolarmente per la fabbricazione di assorbenti igienici e simili.
PT874607E (pt) Aparelho medico metal em folha para o citado aparelho e uso do citado aparelho
NO882406D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive urinstoff- og karbamat-forbindelser.
ES2058651T3 (es) Uso derivados de guanidina para la fabricacion de un medicamento con actividad antagonista de npy.
DE68920624T2 (de) Menschlicher monoklonaler Antikörper, Hybridoma, das ihn herstellt, und pharmazeutisches Mittel.
TR200103432T2 (tr) Engelleyici monoklonal VLA-1 antikoru ve enflamasyonlu hastalıkların tedavisinde kullanımı.
ATE457318T1 (de) Gegen das menschliche bst2 antigen gerichteter monoklonaler antikörper
Patterson-Fortin et al. Serum sickness-like reaction after the treatment of cellulitis with amoxicillin/clavulanate
Perren et al. “Crossed” somatoparaphrenia: an unusual new case and a review of the literature
BR0116010A (pt) Kit imunoterapêutico para o tratamento de tumores
SE8804136L (sv) Absorberande engaangsartikel
GR3006834T3 (pt)
ES2151922T3 (es) Uso de aspirina para la fabricacion de un medicamento para mejorar la perfusion sanguinea en el utero.
HUP0204208A2 (hu) Pruritus kezelésére szolgáló külsőleges gyógyszerkészítmény
BR0213434A (pt) Método para evitar demência em um paciente, e, uso de rosuvastatina ou seu sal farmaceuticamente aceitável
MX9102325A (es) Formas de dosis farmaceuticas de almacalante y procedimiento para su obtencion.